WO2008021483A2 - Procédé de pronostic et diagnostic pour la thérapie d'une maladie - Google Patents

Procédé de pronostic et diagnostic pour la thérapie d'une maladie Download PDF

Info

Publication number
WO2008021483A2
WO2008021483A2 PCT/US2007/018233 US2007018233W WO2008021483A2 WO 2008021483 A2 WO2008021483 A2 WO 2008021483A2 US 2007018233 W US2007018233 W US 2007018233W WO 2008021483 A2 WO2008021483 A2 WO 2008021483A2
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
therapy
genes
expression
gene
Prior art date
Application number
PCT/US2007/018233
Other languages
English (en)
Other versions
WO2008021483A3 (fr
Inventor
Gennadi V. Glinksy
Original Assignee
Ordway Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2007/008088 external-priority patent/WO2007114896A2/fr
Application filed by Ordway Research Institute filed Critical Ordway Research Institute
Priority to EP07836975A priority Critical patent/EP2059615A2/fr
Priority to CA002660857A priority patent/CA2660857A1/fr
Publication of WO2008021483A2 publication Critical patent/WO2008021483A2/fr
Publication of WO2008021483A3 publication Critical patent/WO2008021483A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne de nouveaux procédés et nécessaires pour diagnostiquer la présence de cancer chez u patient, et pour déterminer si un sujet cancéreux est capable de réagir à différents types de schémas thérapeutiques. Les cancers à tester sont notamment ceux de la prostate, des seins, des poumons, de l'estomac, des ovaires, de la vessie, les lymphomes, les mésothéliomes, les médulloblastomes, les gliomes et la leucémie myéloïde aigüe (AML). L'identification de patients résistant à la thérapie au début de leur schéma thérapeutique peut conduire à une modification de la thérapie de façon à obtenir une issue plus favorable. Un mode de réalisation de l'invention concerne un procédé de diagnostic de cancer ou de prédiction d'issue de thérapie anticancéreuse par détection des niveaux d'expression de plusieurs marqueurs dans la même cellule au même moment, et par notation de leur expression comme se situant au-dessus d'un certain seuil, les marqueurs provenant d'une voie particulière se rapportant au cancer, la note étant une indication ou un diagnostic de cancer, ou un pronostic d'échec de thérapie anticancéreuse. Ce procédé convient pour le diagnostic du cancer ou la prédiction des issues des traitements anticancéreux pour divers cancers. Les marqueurs peuvent provenir de n'importe quelle voie impliquée dans la régulation du cancer, et notamment spécifiquement de la voie PcG et de la voie de 'souchitude' au sens de 'caractéristique des cellules souches'. Les marqueurs peuvent être de l'ARNm, de l'ARNmicro, de l'ADN, ou de la protéine.
PCT/US2007/018233 2006-08-17 2007-08-17 Procédé de pronostic et diagnostic pour la thérapie d'une maladie WO2008021483A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07836975A EP2059615A2 (fr) 2006-08-17 2007-08-17 Procédé de pronostic et diagnostic pour la thérapie d'une maladie
CA002660857A CA2660857A1 (fr) 2006-08-17 2007-08-17 Procede de pronostic et diagnostic pour la therapie d'une maladie

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US82270506P 2006-08-17 2006-08-17
US60/822,705 2006-08-17
US82357706P 2006-08-25 2006-08-25
US60/823,577 2006-08-25
US87506106P 2006-12-15 2006-12-15
US60/875,061 2006-12-15
PCT/US2007/008088 WO2007114896A2 (fr) 2006-03-31 2007-04-02 Procédé de pronostic et de diagnostic destiné à une cancérothérapie
US11/732,442 2007-04-02
US11/732,442 US7890267B2 (en) 2006-03-31 2007-04-02 Prognostic and diagnostic method for cancer therapy
USPCT/US2007/008088 2007-04-02
US92234007P 2007-04-05 2007-04-05
US60/922,340 2007-04-05

Publications (2)

Publication Number Publication Date
WO2008021483A2 true WO2008021483A2 (fr) 2008-02-21
WO2008021483A3 WO2008021483A3 (fr) 2009-03-26

Family

ID=56291006

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018233 WO2008021483A2 (fr) 2006-08-17 2007-08-17 Procédé de pronostic et diagnostic pour la thérapie d'une maladie

Country Status (3)

Country Link
EP (1) EP2059615A2 (fr)
CA (1) CA2660857A1 (fr)
WO (1) WO2008021483A2 (fr)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7890267B2 (en) * 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
CN101792793B (zh) * 2009-10-26 2012-05-23 中南大学 miR-182作为胶质瘤发生分子标志物的应用及其检测试剂盒
WO2013003583A3 (fr) * 2011-06-29 2013-04-04 Duke University Mutations somatiques de l'atrx dans le cancer du cerveau
WO2013050331A1 (fr) 2011-10-07 2013-04-11 Universite Montpellier 2 Sciences Et Techniques Procédé permettant d'établir le pronostic d'un gliome
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
US9102920B2 (en) 2008-05-06 2015-08-11 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US9615269B2 (en) 2014-10-02 2017-04-04 At&T Intellectual Property I, L.P. Method and apparatus that provides fault tolerance in a communication network
US9871283B2 (en) 2015-07-23 2018-01-16 At&T Intellectual Property I, Lp Transmission medium having a dielectric core comprised of plural members connected by a ball and socket configuration
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US10072293B2 (en) 2011-03-31 2018-09-11 The Procter And Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
EP3674421A1 (fr) * 2018-12-28 2020-07-01 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Procédés de pronostic du cancer de la prostate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004011625A2 (fr) * 2002-07-31 2004-02-05 University Of Southern California Polymorphismes de prediction de maladies et resultat therapeutique
US20060073479A1 (en) * 2001-11-28 2006-04-06 Frudakis Tony N Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060073479A1 (en) * 2001-11-28 2006-04-06 Frudakis Tony N Single nucleotide polymorphisms and combinations thereof predictive for paclitaxel responsiveness
WO2004011625A2 (fr) * 2002-07-31 2004-02-05 University Of Southern California Polymorphismes de prediction de maladies et resultat therapeutique

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AFFYMETRIX: "GeneChip Human genome U95 Set" DATA SHEET, [Online] 2003, XP002504985 Retrieved from the Internet: URL:http://www.affymetrix.com/support/technical/datasheets/hgu95_datasheet.pdf> *
CHEUNG VIVIAN G ET AL: "Mapping determinants of human gene expression by regional and genome-wide association" NATURE (LONDON), vol. 437, no. 7063, October 2005 (2005-10), pages 1365-1369, XP002504984 ISSN: 0028-0836 cited in the application *
GLINSKY G V ET AL: "Gene expression profiling predicts clinical outcome of prostate cancer" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 113, no. 6, 1 March 2004 (2004-03-01), pages 913-923, XP002395330 ISSN: 0021-9738 *
GLINSKY GENNADI V ET AL: "Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer" JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, US, vol. 115, no. 6, 1 June 2005 (2005-06-01), pages 1503-1521, XP002460132 ISSN: 0021-9738 *
IMAI YASUO ET AL: "C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance" MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION OF CANCER RESEARCH, US, vol. 1, no. 8, 17 June 2002 (2002-06-17), pages 611-616, XP002256816 ISSN: 1535-7163 *
SPIELMAN RICHARD S ET AL: "Common genetic variants account for differences in gene expression among ethnic groups" NATURE GENETICS, vol. 39, no. 2, February 2007 (2007-02), pages 226-231, XP002504983 ISSN: 1061-4036 *
VARAMBALLY S ET AL: "Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression" CANCER CELL, CELL PRESS, US, vol. 8, no. 5, 14 November 2005 (2005-11-14), pages 393-406, XP002395335 ISSN: 1535-6108 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7890267B2 (en) * 2006-03-31 2011-02-15 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
US8700335B2 (en) 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state
US9102920B2 (en) 2008-05-06 2015-08-11 Agency For Science, Technology And Research Method of effecting de-differentiation of a cell
US7897356B2 (en) 2008-11-12 2011-03-01 Caris Life Sciences Methods and systems of using exosomes for determining phenotypes
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
CN101792793B (zh) * 2009-10-26 2012-05-23 中南大学 miR-182作为胶质瘤发生分子标志物的应用及其检测试剂盒
US9128101B2 (en) 2010-03-01 2015-09-08 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
US10072293B2 (en) 2011-03-31 2018-09-11 The Procter And Gamble Company Systems, models and methods for identifying and evaluating skin-active agents effective for treating dandruff/seborrheic dermatitis
US9982306B2 (en) 2011-06-29 2018-05-29 Duke University Somatic mutations in ATRX in brain cancer
WO2013003583A3 (fr) * 2011-06-29 2013-04-04 Duke University Mutations somatiques de l'atrx dans le cancer du cerveau
US11254988B2 (en) 2011-06-29 2022-02-22 The Johns Hopkins University Somatic mutations in ATRX in brain cancer
WO2013050331A1 (fr) 2011-10-07 2013-04-11 Universite Montpellier 2 Sciences Et Techniques Procédé permettant d'établir le pronostic d'un gliome
US9920357B2 (en) 2012-06-06 2018-03-20 The Procter & Gamble Company Systems and methods for identifying cosmetic agents for hair/scalp care compositions
US9615269B2 (en) 2014-10-02 2017-04-04 At&T Intellectual Property I, L.P. Method and apparatus that provides fault tolerance in a communication network
US9871283B2 (en) 2015-07-23 2018-01-16 At&T Intellectual Property I, Lp Transmission medium having a dielectric core comprised of plural members connected by a ball and socket configuration
EP3674421A1 (fr) * 2018-12-28 2020-07-01 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Procédés de pronostic du cancer de la prostate
WO2020136281A1 (fr) * 2018-12-28 2020-07-02 Asociación Centro De Investigación Cooperativa En Biociencias-Cic Biogune Procédés pour le pronostic du cancer de la prostate

Also Published As

Publication number Publication date
EP2059615A2 (fr) 2009-05-20
WO2008021483A3 (fr) 2009-03-26
CA2660857A1 (fr) 2008-02-21

Similar Documents

Publication Publication Date Title
US7890267B2 (en) Prognostic and diagnostic method for cancer therapy
US20080312199A1 (en) Treatments of therapy resistant diseases and drug combinations for treating the same
US20090098538A1 (en) Prognostic and diagnostic method for disease therapy
EP2059615A2 (fr) Procédé de pronostic et diagnostic pour la thérapie d'une maladie
Dawson et al. Triple negative breast cancers: clinical and prognostic implications
Sarver et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states
JP4938672B2 (ja) ｐ５３の状態と遺伝子発現プロファイルとの関連性に基づき、癌を分類し、予後を予測し、そして診断する方法、システム、およびアレイ
US20170283885A1 (en) Algorithms for gene signature-based predictor of sensitivity to mdm2 inhibitors
US20090215036A1 (en) Genetic Alterations Useful For The Response Prediction of Malignant Neoplasia to Taxane-Based Medical Treatments
CA2679208A1 (fr) Procede de prevision de l'occurrence de metastases chez des patients souffrant de cancer du sein
US20160333419A1 (en) Gene signatures associated with sensitivity to mdm2 inhibitors
WO2013052480A1 (fr) Score de risque pronostique de cancer du côlon basé sur des marqueurs
Baehner et al. Genomic signatures of cancer: basis for individualized risk assessment, selective staging and therapy
WO2013025322A2 (fr) Score de risque de pronostic à base d'un marqueur dans le cancer du foie
EP1836313A2 (fr) Procede d'estimation de patients souffrant d'une leucemie myeloide aigue
WO2013082105A1 (fr) Activation de stat3 en tant que marqueur pour classer et pronostiquer des patients atteints du lymphome diffus à grandes cellules b (dlbcl)
Wang et al. The novel tumor‐suppressor Mel‐18 in prostate cancer: its functional polymorphism, expression and clinical significance
Zhao et al. TWIST2: A new candidate tumor suppressor in prostate cancer
Li et al. Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma
EP2550534B1 (fr) Pronostic du cancer de la jonction sophagienne et gastro- sophagienne
EP3144395B1 (fr) Signature de micro-arn utile comme indicateur du risque de récidive précoce chez des patientes atteintes du cancer du sein
KR102016216B1 (ko) 위암의 예후 예측용 마커 및 이의 용도
Song et al. Clinical significance and prognostic value of small nucleolar RNA SNORA38 in breast cancer
US20100015620A1 (en) Cancer-linked genes as biomarkers to monitor response to impdh inhibitors
WO2023081190A1 (fr) Signature d'expression génique basée sur la transition épithélio-mésenchymateuse pour le cancer du rein

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836975

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2660857

Country of ref document: CA

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007836975

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: RU